Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

Stopped early · Phase 2

Conditions studied: Non-Hodgkin's Lymphoma

In brief

Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression

Key facts

Study ID

NCT00582166

Run by

University of Wisconsin, Madison

People needed

18

Starts

2005-01-25

Expected to finish

2013-03-01

Last updated by the study team

2019-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with biopsy-proven non-hodgkins lymphoma of follicular grade 1, 2, or 3
• Meeting FLIPI criteria for intermediate or high risk.
• No prior chemotherapy, radiotherapy or immunotherapy for lymphoma;
• Patients may not have known HIV infection, and must not be Hepatitis B Surface Antigen positive.

You may not qualify if…

• May not be pregnant or breastfeeding, have documented CNS (Central Nervous System) disease, G-CSF (Granulocyte Colony Stimulating Facto) or GM-CSF (Granulocyte/Macrophage Colony Stimulating Factor) within 2 weeks prior

Where it is running

• University Of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.